Literature DB >> 17117132

High passage number of stem cells adversely affects stem cell activation and myocardial protection.

Paul R Crisostomo1, Meijing Wang, George M Wairiuko, Eric D Morrell, Andrew M Terrell, Preethi Seshadri, Un Hui Nam, Daniel R Meldrum.   

Abstract

Progenitor cell plasticity enhances positive remodeling of damaged tissue. We and others have previously shown that progenitor cells may limit apoptosis and modulate inflammation in part by the production of growth factors. However, recent studies suggest that progenitor cells senesce and lose their differentiation potential with increasing time in culture and passage. We hypothesize that murine bone marrow mesenchymal stem cells (MSCs) are cardioprotective against ischemia/reperfusion injury in the isolated perfused rat heart, and that passage number has an adverse effect on MSC activation and cardioprotection. Adult male and female Sprague-Dawley rat hearts were isolated, perfused via Langendorff model, and subjected to ischemia/reperfusion. Mouse MSCs were harvested, cultured, suspended in perfusate, and infused before global index ischemia. Hearts were assigned to controls or infusion with passage 3, 5, or 10 MSCs. In addition, MSCs in culture were stressed by hypoxia and increasing doses of endotoxin (lipopolysaccharide). Mesenchymal stem cell activation was determined by measuring vascular endothelial growth factor production with enzyme-linked immunosorbent assay. All data are reported as mean +/- SEM and were analyzed with 2-way analysis of variance. Differences are considered significant if P < 0.05. Passage 3 murine MSC infusion in hearts before ischemia reduced the depression of left ventricular developed pressure, attenuated the increase of end-diastolic pressure, and reduced the depression of +dP/dT and -dP/dT. However, the MSC protective effect disappeared in hearts infused with passage 5 and passage 10 MSCs. Although hypoxia and lipopolysaccharide resulted in significant activation of MSCs, passage 3 MSCs demonstrated significantly greater vascular endothelial growth factor release than passage 5 and 10 MSCs. Acute murine MSC infusion confers protection in isolated rat hearts. However, high passage number has an adverse effect on MSC activation and protection. This portends limited ex vivo expansion before possible therapeutic use.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17117132     DOI: 10.1097/01.shk.0000235087.45798.93

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  54 in total

1.  Proteomic Profiling of Native Unpassaged and Culture-Expanded Mesenchymal Stromal Cells (MSC).

Authors:  Erika Moravcikova; E Michael Meyer; Mirko Corselli; Vera S Donnenberg; Albert D Donnenberg
Journal:  Cytometry A       Date:  2018-09-13       Impact factor: 4.355

Review 2.  Epidermal growth factor (EGF) treatment on multipotential stromal cells (MSCs). Possible enhancement of therapeutic potential of MSC.

Authors:  Kenichi Tamama; Haruhisa Kawasaki; Alan Wells
Journal:  J Biomed Biotechnol       Date:  2010-02-17

Review 3.  Systems biology approach to developing S(2)RM-based "systems therapeutics" and naturally induced pluripotent stem cells.

Authors:  Greg Maguire; Peter Friedman
Journal:  World J Stem Cells       Date:  2015-05-26       Impact factor: 5.326

4.  Ethanol-mediated compaction and cross-linking enhance mechanical properties and degradation resistance while maintaining cytocompatibility of a nucleus pulposus scaffold.

Authors:  Joshua D Walters; Sanjitpal S Gill; Jeremy J Mercuri
Journal:  J Biomed Mater Res B Appl Biomater       Date:  2019-02-15       Impact factor: 3.368

5.  The simulated microgravity enhances multipotential differentiation capacity of bone marrow mesenchymal stem cells.

Authors:  Nanding Wang; Huan Wang; Jun Chen; Xiaofeng Zhang; Juan Xie; Zhi Li; Jing Ma; Wen Wang; Zongren Wang
Journal:  Cytotechnology       Date:  2013-04-12       Impact factor: 2.058

6.  Glucocorticoid Cell Priming Enhances Transfection Outcomes in Adult Human Mesenchymal Stem Cells.

Authors:  Abby M Kelly; Sarah A Plautz; Janos Zempleni; Angela K Pannier
Journal:  Mol Ther       Date:  2015-10-19       Impact factor: 11.454

7.  Bridging defects in chronic spinal cord injury using peripheral nerve grafts combined with a chitosan-laminin scaffold and enhancing regeneration through them by co-transplantation with bone-marrow-derived mesenchymal stem cells: case series of 14 patients.

Authors:  Sherif M Amr; Ashraf Gouda; Wael T Koptan; Ahmad A Galal; Dina Sabry Abdel-Fattah; Laila A Rashed; Hazem M Atta; Mohammad T Abdel-Aziz
Journal:  J Spinal Cord Med       Date:  2013-11-26       Impact factor: 1.985

8.  Comparison of transplantation of adipose tissue- and bone marrow-derived mesenchymal stem cells in the infarcted heart.

Authors:  Koen E A van der Bogt; Sonja Schrepfer; Jin Yu; Ahmad Y Sheikh; Grant Hoyt; Johannes A Govaert; Jeffrey B Velotta; Christopher H Contag; Robert C Robbins; Joseph C Wu
Journal:  Transplantation       Date:  2009-03-15       Impact factor: 4.939

9.  Nonviral gene delivery to mesenchymal stem cells using cationic liposomes for gene and cell therapy.

Authors:  C Madeira; R D Mendes; S C Ribeiro; J S Boura; M R Aires-Barros; C L da Silva; J M S Cabral
Journal:  J Biomed Biotechnol       Date:  2010-06-24

10.  HIF-1alpha induced-VEGF overexpression in bone marrow stem cells protects cardiomyocytes against ischemia.

Authors:  Ying Dai; Meifeng Xu; Yigang Wang; Zeeshan Pasha; Tingyu Li; Muhammad Ashraf
Journal:  J Mol Cell Cardiol       Date:  2007-04-06       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.